Texas Statutes (Last Updated: January 4, 2014) |
HEALTH AND SAFETY CODE |
Title 6. FOOD, DRUGS, ALCOHOL, AND HAZARDOUS SUBSTANCES |
Subtitle B. ALCOHOL AND SUBSTANCE ABUSE PROGRAMS |
Chapter 461. TEXAS COMMISSION ON ALCOHOL AND DRUG ABUSE |
Sec. 461.017. ADVISORY COMMITTEE ON REDUCING DRUG DEMAND
-
(a) The Drug Demand Reduction Advisory Committee is composed of the following members:
(1) five representatives of the public from different geographic regions of the state who have knowledge and expertise in issues relating to reducing drug demand and who are appointed by the commissioner of the Department of State Health Services; and
(2) one representative of each of the following agencies or offices who is appointed by the executive director or commissioner of the agency or office and who is directly involved in the agency's or office's policies, programs, or funding activities relating to reducing drug demand:
(A) the criminal justice division of the governor's office;
(B) the Criminal Justice Policy Council;
(C) the Department of Family and Protective Services;
(D) the Department of Public Safety of the State of Texas;
(E) the Health and Human Services Commission;
(F) the Texas Alcoholic Beverage Commission;
(G) the Department of State Health Services;
(H) the Texas Council on Offenders with Mental Impairments;
(I) the Texas Department of Criminal Justice;
(J) the Health and Human Services Commission;
(K) the Department of Aging and Disability Services;
(L) the Texas Education Agency;
(M) the Texas Juvenile Probation Commission;
(N) the Texas Youth Commission;
(O) the Department of Assistive and Rehabilitative Services;
(P) the Texas Workforce Commission;
(Q) the Texas Department of Motor Vehicles;
(R) the comptroller of public accounts; and
(S) the adjutant general's department.
(b) The representative of the Texas Commission on Alcohol and Drug Abuse shall serve as the presiding officer of the Drug Demand Reduction Advisory Committee. The commission may provide administrative support to the committee.
(c) The Drug Demand Reduction Advisory Committee shall meet at least once in each quarter of each calendar year on dates determined by the committee.
(d) The Drug Demand Reduction Advisory Committee shall serve as a single source of information for the governor, the legislature, and the public about issues relating to reducing drug demand, including available prevention programs and services.
(e) The Drug Demand Reduction Advisory Committee shall develop a statewide strategy to reduce drug demand. The strategy must:
(1) incorporate multidisciplinary approaches using current empirical research;
(2) include performance-based measurement and accountability standards, short-term objectives, and ten-year targets for reducing drug demand;
(3) coordinate, to the extent possible, the efforts of private sector entities and local, state, and federal agencies, including the Office of National Drug Control Policy and the United States Drug Enforcement Administration, to reduce drug demand; and
(4) provide opportunities for representatives from the public and private sectors to comment on the committee's activities and make recommendations related to the strategy.
(f) The Drug Demand Reduction Advisory Committee shall identify lead or contributing agencies or offices that shall implement the strategy described in Subsection (e). The committee shall coordinate the implementation of the strategy by those agencies or offices.
(g) The Drug Demand Reduction Advisory Committee may establish additional advisory committees composed of representatives from governmental entities and the private sector to assist the committee in carrying out its duties.
(h) Not later than January 15 of each odd-numbered year, the Drug Demand Reduction Advisory Committee shall present to the governor, the lieutenant governor, and the speaker of the house of representatives a report that states:
(1) the committee's progress in developing and coordinating the strategy described in Subsection (e);
(2) the status and funding of state programs relating to reducing drug demand; and
(3) recommendations for legislation to address issues involved in reducing drug demand.